ReViral Drug Discovery for Respiratory Syncytial Virus (RSV)
  • ReViral is a UK-based biotechnology company with a portfolio of drugs to treat RSV infection
  • The most advanced programme, RV521, is a highly potent fusion inhibitor
  • RV521 has received top-line safety and pharmacokinetic data for Phase 1 single and multiple ascending dose (SAD and MAD) trials
  • RV521 is delivered by a convenient oral dose
  • RV521 is now in Phase 2a trial to provide clinical POC
RV521 best-in-class drug to treat RSV infections
  • RV521 is an orally available antiviral with excellent drug-like characteristics
  • Binds to the RSV fusion protein, blocking viral entry and preventing cell-to-cell spread
  • The compound demonstrates potent activity against multiple clinical strains of RSV

RSV Medical Need

  • RSV is the main cause of hospitalisation for children under the age of 5 and a major cause of hospitalisation for the elderly
  • Currently, there are no effective treatments or vaccines available against RSV
  • There is a clear unmet need for a safe and effective treatment with a simple route of administration
Meet the team...
Latest News
ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus

Challenge trial will evaluate RV521 in approximately 70 volunteers

London, UK, 5th September 2017 - ReViral, a UK-based biotech...

ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers

Phase 2a RSV Challenge Study Planned for Q3 2017

London, UK, 24th April 2017 - ReViral, a UK based biotechnology company...

ReViral initiates Phase 1 clinical trial of potent oral inhibitor against Respiratory Syncytial Virus

London, UK, 31st October 2016 - ReViral, an antiviral drug discovery and development company developing innovative therapies against Respiratory...

Contact us...